| 1 | lowering | 5,983 |
| 2 | groene | 5 |
| 3 | jiaweisinisan | 5 |
| 4 | and- | 4 |
| 5 | 42-week | 3 |
| 6 | bowditch | 3 |
| 7 | fev1/predicted | 3 |
| 8 | schepens | 3 |
| 9 | /oxidized | 2 |
| 10 | acute-hyperlipidemia | 2 |
| 11 | borderline-high/high | 2 |
| 12 | hypothesis-that | 2 |
| 13 | lipase-related | 2 |
| 14 | lipids-decreased | 2 |
| 15 | monitoring-based | 2 |
| 16 | oxidation-derived | 2 |
| 17 | peroxidation-derived | 2 |
| 18 | reduction/control | 2 |
| 19 | synthesisers | 2 |
| 20 | 'mozart | 1 |
| 21 | -22.7±13.7 | 1 |
| 22 | -9.6±10.9 | 1 |
| 23 | 117±5 | 1 |
| 24 | 140/diastolic | 1 |
| 25 | 148/diastolic | 1 |
| 26 | 193±7 | 1 |
| 27 | 82/mean | 1 |
| 28 | 86/mean | 1 |
| 29 | absorption-inhibiting | 1 |
| 30 | adenovirus-encoded | 1 |
| 31 | apo-a-defined | 1 |
| 32 | apoa-1-and | 1 |
| 33 | behavior.to | 1 |
| 34 | bilayer-mediated | 1 |
| 35 | carbolinium- | 1 |
| 36 | cellobiose-labeled | 1 |
| 37 | cholesterol.during | 1 |
| 38 | chylomicron-derived | 1 |
| 39 | composition/ | 1 |
| 40 | content-lowering | 1 |
| 41 | control/appropriate | 1 |
| 42 | cooper-induced | 1 |
| 43 | ddavp-stimulated | 1 |
| 44 | education/third | 1 |
| 45 | enviinside | 1 |
| 46 | exposure/cholesterol | 1 |
| 47 | i.despite | 1 |
| 48 | igf-ir-positive | 1 |
| 49 | immuno-specific | 1 |
| 50 | levels/fas | 1 |
| 51 | mean-adjusted | 1 |
| 52 | parameters-total | 1 |
| 53 | peroxidation-originated | 1 |
| 54 | prebeta1 | 1 |
| 55 | preoutcome | 1 |
| 56 | profile-improving | 1 |
| 57 | profiles.clinical | 1 |
| 58 | profiles/hemoglobin | 1 |
| 59 | reapplication+ | 1 |
| 60 | relief-positive | 1 |
| 61 | t-booh-induced | 1 |
| 62 | torcetrapib-induced | 1 |
| 63 | ultracentrifugation-measured | 1 |
| 64 | vivo-labeled | 1 |
| 65 | ≤116 | 1 |
| 1 | 'mozart | 1 |
| 2 | -22.7±13.7 | 1 |
| 3 | -9.6±10.9 | 1 |
| 4 | /oxidized | 2 |
| 5 | 117±5 | 1 |
| 6 | 140/diastolic | 1 |
| 7 | 148/diastolic | 1 |
| 8 | 193±7 | 1 |
| 9 | 42-week | 3 |
| 10 | 82/mean | 1 |
| 11 | 86/mean | 1 |
| 12 | absorption-inhibiting | 1 |
| 13 | acute-hyperlipidemia | 2 |
| 14 | adenovirus-encoded | 1 |
| 15 | and- | 4 |
| 16 | apo-a-defined | 1 |
| 17 | apoa-1-and | 1 |
| 18 | behavior.to | 1 |
| 19 | bilayer-mediated | 1 |
| 20 | borderline-high/high | 2 |
| 21 | bowditch | 3 |
| 22 | carbolinium- | 1 |
| 23 | cellobiose-labeled | 1 |
| 24 | cholesterol.during | 1 |
| 25 | chylomicron-derived | 1 |
| 26 | composition/ | 1 |
| 27 | content-lowering | 1 |
| 28 | control/appropriate | 1 |
| 29 | cooper-induced | 1 |
| 30 | ddavp-stimulated | 1 |
| 31 | education/third | 1 |
| 32 | enviinside | 1 |
| 33 | exposure/cholesterol | 1 |
| 34 | fev1/predicted | 3 |
| 35 | groene | 5 |
| 36 | hypothesis-that | 2 |
| 37 | i.despite | 1 |
| 38 | igf-ir-positive | 1 |
| 39 | immuno-specific | 1 |
| 40 | jiaweisinisan | 5 |
| 41 | levels/fas | 1 |
| 42 | lipase-related | 2 |
| 43 | lipids-decreased | 2 |
| 44 | lowering | 5,983 |
| 45 | mean-adjusted | 1 |
| 46 | monitoring-based | 2 |
| 47 | oxidation-derived | 2 |
| 48 | parameters-total | 1 |
| 49 | peroxidation-derived | 2 |
| 50 | peroxidation-originated | 1 |
| 51 | prebeta1 | 1 |
| 52 | preoutcome | 1 |
| 53 | profile-improving | 1 |
| 54 | profiles.clinical | 1 |
| 55 | profiles/hemoglobin | 1 |
| 56 | reapplication+ | 1 |
| 57 | reduction/control | 2 |
| 58 | relief-positive | 1 |
| 59 | schepens | 3 |
| 60 | synthesisers | 2 |
| 61 | t-booh-induced | 1 |
| 62 | torcetrapib-induced | 1 |
| 63 | ultracentrifugation-measured | 1 |
| 64 | vivo-labeled | 1 |
| 65 | ≤116 | 1 |
| 1 | reapplication+ | 1 |
| 2 | and- | 4 |
| 3 | carbolinium- | 1 |
| 4 | composition/ | 1 |
| 5 | prebeta1 | 1 |
| 6 | 117±5 | 1 |
| 7 | ≤116 | 1 |
| 8 | -22.7±13.7 | 1 |
| 9 | 193±7 | 1 |
| 10 | -9.6±10.9 | 1 |
| 11 | acute-hyperlipidemia | 2 |
| 12 | immuno-specific | 1 |
| 13 | 140/diastolic | 1 |
| 14 | 148/diastolic | 1 |
| 15 | torcetrapib-induced | 1 |
| 16 | t-booh-induced | 1 |
| 17 | cooper-induced | 1 |
| 18 | adenovirus-encoded | 1 |
| 19 | cellobiose-labeled | 1 |
| 20 | vivo-labeled | 1 |
| 21 | apo-a-defined | 1 |
| 22 | ultracentrifugation-measured | 1 |
| 23 | monitoring-based | 2 |
| 24 | lipids-decreased | 2 |
| 25 | bilayer-mediated | 1 |
| 26 | lipase-related | 2 |
| 27 | ddavp-stimulated | 1 |
| 28 | peroxidation-originated | 1 |
| 29 | fev1/predicted | 3 |
| 30 | mean-adjusted | 1 |
| 31 | oxidation-derived | 2 |
| 32 | peroxidation-derived | 2 |
| 33 | chylomicron-derived | 1 |
| 34 | /oxidized | 2 |
| 35 | apoa-1-and | 1 |
| 36 | education/third | 1 |
| 37 | enviinside | 1 |
| 38 | preoutcome | 1 |
| 39 | groene | 5 |
| 40 | control/appropriate | 1 |
| 41 | i.despite | 1 |
| 42 | relief-positive | 1 |
| 43 | igf-ir-positive | 1 |
| 44 | lowering | 5,983 |
| 45 | content-lowering | 1 |
| 46 | cholesterol.during | 1 |
| 47 | absorption-inhibiting | 1 |
| 48 | profile-improving | 1 |
| 49 | bowditch | 3 |
| 50 | borderline-high/high | 2 |
| 51 | 42-week | 3 |
| 52 | profiles.clinical | 1 |
| 53 | parameters-total | 1 |
| 54 | exposure/cholesterol | 1 |
| 55 | reduction/control | 2 |
| 56 | 82/mean | 1 |
| 57 | 86/mean | 1 |
| 58 | jiaweisinisan | 5 |
| 59 | profiles/hemoglobin | 1 |
| 60 | behavior.to | 1 |
| 61 | levels/fas | 1 |
| 62 | schepens | 3 |
| 63 | synthesisers | 2 |
| 64 | hypothesis-that | 2 |
| 65 | 'mozart | 1 |